Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX – Get Free Report)’s share price rose 2.7% during mid-day trading on Monday . The company traded as high as $3.30 and last traded at $2.69. Approximately 578,951 shares changed hands during mid-day trading, an increase of 519% from the average daily volume of 93,476 shares. The stock had previously closed at $2.62.
Salarius Pharmaceuticals Stock Performance
The company has a market capitalization of $3.87 million, a PE ratio of -0.33 and a beta of 0.83. The company’s 50-day moving average is $1.64 and its 200 day moving average is $1.78.
About Salarius Pharmaceuticals
Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.
Further Reading
- Five stocks we like better than Salarius Pharmaceuticals
- Why Invest in High-Yield Dividend Stocks?
- 3 Stocks to Gain From Donald Trump’s External Revenue Service
- What is the S&P/TSX Index?
- AMD: Loop Capital’s Buy Rating Reinforces Investor Confidence
- How to Invest in the FAANG Stocks
- Momentum Is Building for Qualcomm to Have a Strong Run in 2025
Receive News & Ratings for Salarius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Salarius Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
